Resources

Blog

Scientific Publications

The role of regulatory T cells in neurodegenerative diseases

The role of regulatory T cells in nervous system pathologies

The Trojan horse – neuroinflammatory impact of T cells in neurodegenerative diseases

Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders

TREGking From Gut to Brain: The Control of Regulatory T Cells Along the Gut-Brain Axis

Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease

Regulatory impairment in untreated Parkinson’s disease is not restricted to Tregs: other regulatory populations are also involved

Interleukin-2 expands neuroprotective regulatory T cells in Parkinson’s disease

Treg Cells Attenuate Neuroinflammation and Protect Neurons in a Mouse Model of Parkinson’s Disease

Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinson’s disease

Adoptive therapy with amyloid-β specific regulatory T cells alleviates Alzheimer’s disease

The Characterization of Regulatory T-Cell Profiles in Alzheimer’s Disease and Multiple Sclerosis

Restoring regulatory T-cell dysfunction in Alzheimer’s disease through ex vivo expansion

Regulatory T cells delay disease progression in Alzheimer-like pathology

Neuroprotective effects of CD4+CD25+Foxp3+ regulatory T cells in a 3xTg-AD Alzheimer’s disease model

IL-2-based approaches to Treg enhancement

Alzheimer’s Disease: From Immune Homeostasis to Neuroinflammatory Condition

Ex vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer’s disease

Regulatory T cells delay disease progression in Alzheimer-like pathology

Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies

Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study

ALS patients’ regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity

Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis

Elevated acute phase proteins reflect peripheral inflammation and disease severity in patients with amyotrophic lateral sclerosis

Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival

Restoring regulatory T-cell dysfunction in Alzheimer’s disease through ex vivo expansion

Coya is currently enrolling the ALSTARS Phase 2 trial for Coya 302 for people living with ALS across the U.S. and Canada. More information about the ALSTARS trial is available on https://clinicaltrials.gov/study/NCT07161999 or https://trials.coyatherapeutics.com/